Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported Other Non-Current Assets of $573000.0 for Q1 2026, up 13.69% on a YoY basis from $504000.0 in Q1 2025, and up 2.69% quarter-over-quarter from $558000.0 in Q4 2025.
Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported Other Non-Current Assets for 17 years, with the latest figure at $573000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 13.69% year-over-year to $573000.0; the trailing twelve-month figure through Mar 2026 stood at $573000.0 (up 13.69% YoY), and the FY2025 full-year result was $558000.0, down 9.12% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $573000.0, up from $558000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $639000.0 in Q1 2022, with the low at $504000.0 in Q2 2022.
- Historically, Other Non-Current Assets has averaged $577176.5 across 5 years, with a median of $588000.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets decreased 17.38% — and 2023, when it gained 16.67%.
- Lineage Cell Therapeutics' Other Non-Current Assets stood at $627000.0 in 2022, then decreased by 7.97% to $577000.0 in 2023, then climbed by 6.41% to $614000.0 in 2024, then slipped by 9.12% to $558000.0 in 2025, then climbed by 2.69% to $573000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $573000.0 (Q1 2026), $558000.0 (Q4 2025), and $539000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 60,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | 573,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 573,000.00 |
| Dec 31, 2025 | 558,000.00 |
| Sep 30, 2025 | 539,000.00 |
| Jun 30, 2025 | 511,000.00 |
| Mar 31, 2025 | 504,000.00 |
| Dec 31, 2024 | 614,000.00 |
| Sep 30, 2024 | 606,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 596,000.00 |
| Dec 31, 2023 | 577,000.00 |
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 588,000.00 |
| Mar 31, 2023 | 635,000.00 |
| Dec 31, 2022 | 627,000.00 |
| Sep 30, 2022 | 591,000.00 |
| Jun 30, 2022 | 504,000.00 |
| Mar 31, 2022 | 639,000.00 |
| Dec 31, 2021 | 630,000.00 |
| Sep 30, 2021 | 614,000.00 |
| Jun 30, 2021 | 610,000.00 |